<DOC>
	<DOCNO>NCT00565370</DOCNO>
	<brief_summary>There strong scientific rationale explore role sorafenib capecitabine cisplatin ( XP ) AGC . XP new standard care AGC sorafenib novel signal transduction inhibitor prevents tumor cell proliferation angiogenesis blockade Raf/MEK/ERK pathway level Raf kinase receptor tyrosine kinases VEGF-R2 PDGFR-beta .</brief_summary>
	<brief_title>Capecitabine Cisplatin ( XP ) +Sorafenib Advanced Gastric Cancer ( AGC )</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Having give sign write informed consent Unresectable advance gastric adenocarcinoma , initially diagnose recurred No history chemotherapy radiation Measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) Age 1875 year Estimated life expectancy 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Adequate bone marrow function ( absolute neutrophil count &gt; 1,500/µL , platelet &gt; 100,000/µL , hemoglobin &gt; 8g/dl ) , Adequate kidney function ( creatinine clearance &gt; 60 ml/min ) Adequate liver function ( bilirubin &lt; 2.0 mg/dL , transaminases level &lt; 3 time upper normal limit [ 5 time patient liver metastasis ] ) Past concurrent history neoplasm gastric adenocarcinoma , except curatively treat nonmelanoma skin cancer situ carcinoma cervix uteri Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start Presence central nervous system metastasis Obvious peritoneal seed bowel obstruction Evidence serious gastrointestinal bleeding Peripheral neuropathy ( National Cancer Institute Common Terminology Criteria Adverse Event version 3.0 &gt; Grade I ) History significant neurologic psychiatric disorder Pregnant lactate woman , woman childbearing potential employ adequate contraception Other serious illness medical condition Known allergy study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>capecitabine</keyword>
	<keyword>cisplatin</keyword>
	<keyword>sorafenib</keyword>
	<keyword>phase I</keyword>
	<keyword>phase II</keyword>
</DOC>